3. Mavacamten can offer totargeted drug for hypertrophic cardiomyopathy
Mavacamten is Bristol Myers Squibb’s new drug for the treatment of patients with symptomatic hypertrophic cardiomyopathy (oHCM). According to the report, the drug could bring “new hope” to patients and doctors if it hits the US market. If approved, it would be the first drug explicitly dedicated to treating HCM.
The FDA is expected to announce its final decision on approving the drug by the end of April.
“We are confident in the profile of mavacamten,” said Samit Hirawat, MD, executive vice president and medical director of global drug development for Bristol Myers Squibb, in a 2021 statement. “This cardiac myosin inhibitor, first of its class, has demonstrated clinically meaningful improvements in symptoms, functional status and quality of life in symptomatic patients with oHCM in the pivotal phase EXPLORE-HCM test. We look forward to continuing to work closely with the FDA to bring this important medicine to patients. »
MyoKardia, the original maker of the drug, was acquired by Bristol Myers Squibb in October 2020 for $13.1 billion.
4. Predictive analytics can identify hypertensive patients at risk
High blood pressure usually has no symptoms, but greatly increases the risk of serious health problems, including heart disease, heart failure, and stroke. Effective treatment options exist, but many adults are unaware they have high blood pressure until they experience a serious health crisis. Using machine learning, physicians are able to better select more effective drugs, drug combinations, and dosages to improve hypertension control. The Cleveland Clinic said artificial intelligence (AI) also allows physicians to predict cardiovascular morbidities and better focus prevention efforts. Predictive analytics provides providers with the key that could open the door to preventing hypertension and many other diseases.
Read the full Cleveland Clinic report here.
Too much Tylenol? Daily use of acetaminophen may be harmful for hypertensive patients
Hospitals are seeing more patients with uncontrolled blood pressure
FDA approves inclisiran, a six-monthly injection that lowers cholesterol
FDA delays decision on Bristol Myers Squibb’s new heart disease drug